Sanofi India Limited has successfully completed the shareholder approval process for Deepak Arora's appointment as Managing Director, with the postal ballot concluding on December 17, 2025. The voting results demonstrate strong shareholder confidence in the new leadership appointment.

Shareholder Approval Results

The postal ballot voting, conducted through remote e-voting from November 18 to December 17, 2025, yielded decisive results for both resolutions. The scrutinizer's report, prepared by Gaurav Sainani of SGGS Associates, confirmed the approval of Deepak Arora's dual appointment.

Voting Process and Compliance

The postal ballot process was conducted in full compliance with Regulation 44 of SEBI Listing Regulations and the Companies Act, 2013. The cut-off date for eligible voters was November 14, 2025, and the notice was dispatched to shareholders via email on November 17, 2025.

New Leadership at the Helm

Deepak Arora's appointment as Managing Director, effective from October 27, 2025, brings over three decades of pharmaceutical and healthcare experience to Sanofi India. His career spans across various geographies including North America, Europe, Middle East, and Africa, where he has held leadership positions in commercial, sales, marketing, and general management roles.

Key Responsibilities and Strategic Vision

In his new position, Arora will be tasked with defining and driving the strategic vision for Sanofi in India, spearheading strategic priorities to boost innovation and agility, fostering operational excellence across all functions, and championing the company's Diversity, Equity, and Inclusion culture.

Management Transition Details

Rachid Ayari stepped down from his position as Interim Managing Director on October 26, 2025, after serving in the interim role since July 21, 2025. Ayari continues to serve as Whole-time Director and Chief Financial Officer of Sanofi India. The Board has also authorized Deepak Arora to determine the materiality of events and make stock exchange disclosures, alongside other Key Managerial Personnel.

This management change, now formally approved by shareholders, marks a new chapter for Sanofi India as it continues its mission to promote health and chase the miracles of science to improve people's lives across the entire health spectrum in India.

Sanofi India Limited has successfully concluded its postal ballot process, with shareholders overwhelmingly approving the appointment of Deepak Arora as Director and Managing Director of the company. The voting results, announced on December 18, 2025, show strong shareholder confidence in the proposed leadership change.

Voting Results and Approval

The postal ballot concluded with decisive approval for both resolutions:

The e-voting process, conducted through NSDL's platform, saw participation from 23,03,062 shareholders representing 86.74% of the total voting rights.

Appointment Details

With shareholder approval secured, Mr. Deepak Arora's appointment is now confirmed for a three-year term from October 27, 2025, to October 26, 2028. The 52-year-old executive brings over 30 years of pharmaceutical industry experience to his new role.

Remuneration Structure

The approved remuneration package for Mr. Arora includes:

Additional benefits encompass provident fund, gratuity, increments, relocation support, leave travel allowance, insurance coverage, and other perquisites as per company policy.

Voting Process and Timeline

The postal ballot process was conducted entirely through electronic voting:

• Notice Circulation: November 17, 2025
• E-voting Period: November 18, 2025 (9:00 AM) to December 17, 2025 (5:00 PM)
• Results Declaration: December 18, 2025
• Cut-off Date: November 14, 2025

Mr. Gaurav Sainani from SGGS Associates served as the scrutinizer for the voting process, ensuring transparency and compliance with regulatory requirements.

Professional Background and Regulatory Approval

Mr. Arora holds a Bachelor's degree in Botany & Zoology from the University of Lucknow and an MBA from Indira Gandhi National Open University. His extensive experience spans sales and marketing leadership, brand development, product management, and business acquisition across local and international markets including the US, Europe, Japan, Africa, and the Middle East.

The appointment requires Central Government approval as Mr. Arora has not been residing in India for the required 12 months prior to the appointment date, in accordance with Schedule V of the Companies Act, 2013.

The successful approval of both resolutions demonstrates strong shareholder confidence in the Board's recommendation and Mr. Arora's capabilities to lead Sanofi India through its next phase of growth in the Indian pharmaceutical market.